𝔖 Bobbio Scriptorium
✦   LIBER   ✦

r-interferon alfa–2b/ribavirin combined therapy followed by low-dose r-Interferon alfa-2b in chronic hepatitis C interferon nonresponders

✍ Scribed by A. Perasso; G. Testino; F. Ansaldi; V. Venturino; G.C. Icardi

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
30 KB
Volume
29
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy of hepatitis C: Meta-analysis of
Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
✍ R L Carithers Jr; S S Emerson 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

We performed an independent meta-analysis of all available blind, placebo-controlled trials confirmed the efficacy of this randomized clinical trials of interferon alfa-2b in patients with agent in normalizing alanine aminotransferase (ALT) values chronic hepatitis C. Articles published between 1986

Cost-effectiveness of interferon alfa 2b
Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C
✍ W. Ray Kim; John J. Poterucha 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views

In their paper in the November issue of HEPATOLOGY, Younossi et al. 1 may have overestimated the cost effectiveness of interferon-ribavirin treatment. This mainly stems from their failure to take into account the fact that patients who achieve sustained response are not homogenous with respect to th

Interferon alfa-2b in combination with r
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics
✍ Regino P. González-Peralta; Deirdre A. Kelly; Barbara Haber; Jean Molleston; Kar 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views

Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur. We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We determined the optimal ribavirin dose in an initial coh

Prediction of response during interferon
Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
✍ M J Tong; L M Blatt; J G McHutchison; R L Co; A Conrad 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 1 views

Patients with chronic hepatitis C (n Å 103) were treated cases of acute hepatitis C occur on an annual basis, and an estimated 8,000 to 10,000 deaths occur each year of compli-for 24 weeks with interferon alfa 2b and followed up for 24 weeks after cessation of therapy (week 48). When hepatitis catio

Response to higher doses of interferon a
Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 1 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi